Any current/future new fundraising through debt or equity?

No specific mention of any new fundraising through debt or equity in the current quarter or near future. The company is currently net cash positive with strong balance sheet and has "dry powder" (available capacity) to raise working capital by another INR350-400 crores if needed. They have sufficient land, infrastructure, and buildings in place for expansion and can add equipment quickly without large lead times. The company is actively scouting for both organic and inorganic growth opportunities, including acquisitions, but no new deals/raises announced yet. IPO proceeds utilization stands at

Any current/future capex/capital investment/strategic investment?

Regular capex and maintenance ongoing at 1% to 2% of revenues. Ability to quickly execute additional capex for specific customer needs; equipment/line additions have 3-6 months lead time. Land, infrastructure, and building capacity already in place, enabling rapid scaling with new equipment. Utilization of IPO proceeds: 15.4% deployed towards capex as of December 2025, with more planned in coming quarters. Focus on investments in advanced manufacturing technologies (MES, automation, digitization) to improve efficiency and quality. Continued investment in B2S capabilities and technology stacks

Future growth expectations in sales/revenue/volumes?

FY '27 expected to see double-digit growth in build-to-spec (B2S) revenue, increasing from around 6-7% in FY '26 to over 10%. Strong order intake momentum with book-to-bill ratio >1.5 YTD, indicating robust revenue visibility. Q4 FY '26 anticipated to have positive year-on-year revenue growth, marking a turnaround from recent declines. FY '27 revenue growth expected to be substantial, driven by new sales team efforts, industry mix shift, and expansion into new geographies and segments (aerospace, industrial, medical, automotive). Build-to-spec programs beginning revenue realization in

Future growth expectations in earnings/operating earnings/profits/EPS?

FY '27 expected to show slight double-digit growth in revenue with good growth from FY '28 onwards, driven by B2S programs and improved industry mix. Margins anticipated to improve due to operating leverage, industry mix shift, and build-to-spec (B2S) ramp-up; margins to sustain around 10% range. Strong order book and diversified customer base providing robust revenue visibility and support for future growth. Operational efficiencies and scale benefits expected to drive further margin expansion and profitability. Investment in sales leadership and new technologies underpins confidence

Current/ Expected Orderbook/ Pending Orders?

As of Q3 FY '26, the order book stands strong at INR 23.5 billion (approximately INR 2,350 crores), reflecting a quarter-on-quarter increase of INR 583 million. This marks the third consecutive quarter of positive momentum in order intake. The orders booked carry healthy and structurally improved margin profiles compared to historical levels. The book-to-bill ratio stands at 1.56 on a year-to-date basis, indicating robust revenue visibility. New orders and strong repeat business contributed to a healthy quarterly order intake of INR 387 crores. The order book's margins are projected to be bett

IN US

Sale is live|00:00:00left today

Cyient DLM LtdQ4 FY27Aerospace & Defense

Cyient DLM Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹462P/E: 45.1Market Cap: ₹3.3K CrSector: Aerospace & Defense

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→FY '27 expected to see double-digit growth in build-to-spec (B2S) revenue, increasing from around 6-7% in FY '26 to over 10%.
→Strong order intake momentum with book-to-bill ratio >1.5 YTD, indicating robust revenue visibility.
→Q4 FY '26 anticipated to have positive year-on-year revenue growth, marking a turnaround from recent declines.
→FY '27 revenue growth expected to be substantial, driven by new sales team efforts, industry mix shift, and expansion into new geographies and segments (aerospace, industrial, medical, automotive).
→Build-to-spec programs beginning revenue realization in FY '26, with significant scaling and margin expansion expected from FY '27 onwards.
→Strong order book (~INR 2400 crores) with healthy margins, supporting 20-25% growth projection for FY '27.
→Continued investments in sales, technology, and operational excellence to support long-term growth and improved margins.

Margin guidance

Category 1

→FY '27 expected to show slight double-digit growth in revenue with good growth from FY '28 onwards, driven by B2S programs and improved industry mix.
→Margins anticipated to improve due to operating leverage, industry mix shift, and build-to-spec (B2S) ramp-up; margins to sustain around 10% range.
→Strong order book and diversified customer base providing robust revenue visibility and support for future growth.
→Operational efficiencies and scale benefits expected to drive further margin expansion and profitability.
→Investment in sales leadership and new technologies underpins confidence in sustained growth and margin expansion.
→Positive net cash position and balance sheet strength to support capacity expansion and strategic initiatives, including organic and inorganic growth.
→Earnings and PAT margins expected to improve as scale returns, with normalized EBITDA margin at 10.2% in latest quarter showing potential upside.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of any new fundraising through debt or equity in the current quarter or near future.
→The company is currently net cash positive with strong balance sheet and has "dry powder" (available capacity) to raise working capital by another INR350-400 crores if needed.
→They have sufficient land, infrastructure, and buildings in place for expansion and can add equipment quickly without large lead times.
→The company is actively scouting for both organic and inorganic growth opportunities, including acquisitions, but no new deals/raises announced yet.
→IPO proceeds utilization stands at 93.2%, with working capital and capex planned based on business needs.
→Overall, the financial position is strong, and expansions are planned to be funded from internal accruals and available financial resources without immediate need for new fundraising.

Order book

Yes

→As of Q3 FY '26, the order book stands strong at INR 23.5 billion (approximately INR 2,350 crores), reflecting a quarter-on-quarter increase of INR 583 million.
→This marks the third consecutive quarter of positive momentum in order intake.
→The orders booked carry healthy and structurally improved margin profiles compared to historical levels.
→The book-to-bill ratio stands at 1.56 on a year-to-date basis, indicating robust revenue visibility.
→New orders and strong repeat business contributed to a healthy quarterly order intake of INR 387 crores.
→The order book's margins are projected to be better than current margins, supporting double-digit profitability.
→Build-to-spec revenue is currently about 6-7% of total revenue and is expected to grow to double digits in FY '27, aiding margin expansion.
→The backlog supports positive growth visibility for Q4 and FY '27, with expectations of a 20-25% revenue growth in FY '27.

Capex plans

Yes

→Regular capex and maintenance ongoing at 1% to 2% of revenues.
→Ability to quickly execute additional capex for specific customer needs; equipment/line additions have 3-6 months lead time.
→Land, infrastructure, and building capacity already in place, enabling rapid scaling with new equipment.
→Utilization of IPO proceeds: 15.4% deployed towards capex as of December 2025, with more planned in coming quarters.
→Focus on investments in advanced manufacturing technologies (MES, automation, digitization) to improve efficiency and quality.
→Continued investment in B2S capabilities and technology stacks to scale design-led growth.
→Strategic inorganic growth pursued via acquisitions to expand geographies and capabilities; previously pursued but called off a $17.75 million M&A deal, with ongoing scouting.
→Expect balanced capital deployment between organic growth, technology investment, and potential acquisitions.

How does Cyient DLM Ltd rank vs peers in Aerospace & Defense?

Pro feature

1Cyient DLM Ltd

Rev 2Mar 1

See full Aerospace & Defense sector rankings

Want more stocks like Cyient DLM Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio